The Latest Breaking News from Moderna

A sudden rise in the unemployment rate tempered today's strong payroll numbers.

The European Medicines Agency (EMA) has backed two separate Covid-19 booster vaccines updated to target the omicron variant of Covid-19 and developed by drugmakers Moderna and BioNTech-Pfizer.

Last week, the FDA authorized both Pfizer and Moderna's Omicron-specific jabs. Experts say to get them as soon as they are available to you.

Vaccine makers' stocks sank Wednesday despite Food and Drug Administration authorization for their updated Covid booster shots.

U.S. regulators have authorized updated COVID-19 boosters, the first to directly target today's most common omicron strain

The Food and Drug Administration granted emergency authorization to Pfizer and Moderna for updated COVID-19 booster shots.

Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular…

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Imagine companies three times as profitable as the S&P 500 — putting them in a good position to handle whatever comes next.